| Date | Title | Description |
| 04.11.2024 | Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo | Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 million as of June 30
NEW YORK and WALTHAM,... |
| 01.08.2024 | Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update | – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 –
– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
– Pivotal AUGME... |
| 31.07.2024 | Navigating the Future of Cancer Treatment and Cybersecurity: A Dual Perspective on Innovation | In the ever-evolving landscape of healthcare and technology, two recent developments stand out: Syndax Pharmaceuticals’ progress with revumenib and Exiger’s acquisition of aDolus. Both represent critical advancements in their respective fie... |
| 31.07.2024 | A New Dawn in Treatment: CNT201 and Revumenib Pave the Way for Hope | In the ever-evolving landscape of medical science, two recent developments shine like beacons of hope. Connext’s CNT201 for Dupuytren's contracture and Syndax’s revumenib for KMT2Ar acute leukemia are not just treatments; they represent the... |
| 29.07.2024 | Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia | – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review –
WALTHAM, Mass., July 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an... |
| 14.06.2024 | Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress | - Data continue to support revumenib's potential to enhance current standard of care agents -
- 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT... |
| 15.05.2024 | Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors | WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., ... |
| 08.05.2024 | Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update | – NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 –
– BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August... |
| 28.03.2024 | Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia | – Topline data expected in 4Q24 could support sNDA filing in 1H25 –
– Revumenib has the potential to address $2 billion mNPM1 and KMT2Ar R/R acute leukemia
U.S. market opportunity –
WALTHAM, Mass., March 28, 2024 /PRNewswire/ -- Syndax Phar... |
| 26.03.2024 | Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia | – PDUFA action date set for September 26, 2024 –
– NDA being reviewed under FDA's RTOR program –
WALTHAM, Mass., March 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an ... |
| 02.10.2023 | Syndax’s leukemia drug succeeds in pivotal study | Syndax Pharmaceuticals’ treatment for a genetically defined form of advanced leukemia met its goal in a pivotal study, leading to complete remission for about a quarter of patients in the trial.
The results, disclosed Monday, will set in mo... |
| 07.04.2023 | Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WALTHAM, Mass., April 7, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. SNDX, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 3, 2023 the Company granted ind... |
| 11.12.2022 | Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting | - 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute leukemia patients treated at RP2D -
- 9 of 12 patients who underwent stem cell transplant after achieving a response with... |
| 07.12.2022 | Syndax Announces Pricing of $150 Million Public Offering of Common Stock | WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") SNDX, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies... |
| 04.02.2022 | Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development | WALTHAM, Mass., Feb. 3, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer... |
| 20.01.2022 | Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference | WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cance... |
| 07.01.2022 | Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference | WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer... |
| 22.12.2021 | Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia | WALTHAM, Mass., Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cance... |
| 16.12.2021 | Syndax Announces Pricing of $75.3 Million Public Offering | WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cance... |
| 24.11.2021 | Patient death prompts clinical trial pause for Kura Oncology leukemia drug | A patient in an early-stage clinical trial evaluating a Kura Oncology cancer drug has died, leading the FDA to pause the study while an inquiry aims to find out whether the death was related to a known complication of treatments for acute m... |
| 31.01.2020 | Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million | – Offering led by premier life sciences investors including BVF, Boxer Capital and AI Life Sciences –– Shares offered at $8, a 20% premium to the January 30, 2020 market close –– Agreement with Hercules would provide Company with additional... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 04.01.2016 | Biotech Startups Hit the Ground Running, With Six Filing IPO Plans Today | If we had to gamble on it, we’d bet the IPO market will be far more brisk this year than last year, which was the worst year for tech IPOs in particular since 2009.
Even still, it came as a bit of a surprise today when not one or three but ... |
| 25.08.2015 | Syndax Pharmaceuticals Grabs $80M |
WALTHAM, MA, Syndax Pharmaceuticals announced today that it has completed an $80 million Series C financing.
>> Click here for more funding data on Syndax Pharmaceuticals
>> To export Syndax Pharmaceuticals funding data to P... |
| 24.08.2015 | Syndax Raises $80 Million in Series C Financing | - |
| 24.08.2015 | Syndax Pharmaceuticals Closes $80M in Series C Funding | Syndax Pharmaceuticals Inc., a Waltham, Massachusetts-based biopharmaceutical company focused on treating cancer, closed $80m in Series C funding.
The round was led by Fidelity Management & Research Company and Delos Capital Fund LP led... |
| 24.08.2015 | Sporty Monday: FanDuel Keeps Buying and the LA Dodgers Start an Accelerator | If you're a sports fan, today's funding roundup should make you happy beyond belief. The Los Angeles Dodgers officially opened their new accelerator and have dedicated their efforts there to helping entrepreneurs with sports related compani... |
| 24.08.2015 | Syndax Raises $80 Million in Series C Financing | |
| 17.04.2015 | Stealth San Diego startup Metacrine raising $33M. Are we reassembling the Seragon team? | Evans, Metacrine’s founder, is a lauded gene expression researcher at the Salk Institute who has a number of successful (cancer and hormone-related) biotechs under his belt.
Evans is known, according to his Salk profile, for his seminal hor... |
| 22.09.2014 | Despite IPO plans, Syndax raises another $5 million for epigenetic breast cancer treatment | The company is collaborating with the National Cancer Institute, and has several other Phase II and Phase I trials in breast cancer underway. Additionally, it’s testing the compound in patients with lung cancer. The company described its te... |
| 27.08.2013 | Syndax snags $26.6M round for Phase III breast cancer study | Waltham, MA-based Syndax Pharmaceuticals took a big step to the threshold of a key pivotal study for its lead cancer therapy today, completing a $26.6 million venture round. The funds will pay for a Phase III study of entinostat, an HDAC in... |
| 27.08.2013 | Syndax Pharmaceuticals Inks $26.6M Series B |
WALTHAM, MA, Firm developing epigenetic therapies for treatment-resistant cancers, today announced it has secured a $26.6 million Series B financing.
>> Click here for more funding data on Syndax Pharmaceuticals
>> To export... |
| 27.08.2013 | Syndax Pharmaceuticals Secures $26.6M Series B Financing | Syndax Pharmaceuticals Inc., a Waltham, MA-based developer of epigenetic therapies for treatment-resistant cancers, secured a $26.6m Series B financing.
Backers included Domain Associates, MPM Capital, Forward Ventures and RusnanoMedInvest ... |
| 27.08.2013 | Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment - Resistant Cancers | |
| 15.08.2010 | Syndax Pharmaceuticals Raises $6M | Syndax Pharmaceuticals, Inc., a Waltham, MA-based clinical-stage epigenetics oncology company, has issued $6m in convertible notes and warrants to its Series A investors.
All existing investors, including Domain Associates, MPM Capital, Ava... |
| - | Stealth San Diego startup Metacrine raising $33M. Are we reassembling the Seragon team? | An interesting new San Diego biotech – Metacrine – is in the works.
CFO Trisha Millican said the company’s raised $6.85 million, and is aiming for $33 million – but otherwise is keeping silent on its dealings.
So time for some extrapolation... |
| - | Despite IPO plans, Syndax raises another $5 million for epigenetic breast cancer treatment | A company in the burgeoning field of epigenetics has raised about $5 million in debt financing, right on the heels of refiling for an initial public offering.
Syndax Pharmaceuticals, a late-stage Massachusetts biotech, postponed an IPO from... |
| - | Patient death prompts clinical trial pause for Kura Oncology leukemia drug | A patient in an early-stage clinical trial evaluating a Kura Oncology cancer drug has died, leading the FDA to pause the study while an inquiry aims to find out whether the death was related to a known complication of treatments for acute m... |